Business
Profounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States
Profounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatmen...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nProfounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nProfounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States\nCanada NewsWire\nORLANDO, Fla. and MONTREAL, March 22, 2016\n\n\n\n- Launch follows September 25, 2015 Licensing Agreement with a wholly-owned subsidiary of Knight Therapeutics Inc. (TSX:GUD) (\"Knight\").\n\n\n\nORLANDO, Fla. and MONTREAL, March 22, 2016 /CNW/ -- Profounda, Inc. (\"Profounda\") announced today that Impavido® (miltefosine) is now available in the United States. Impavido is the first and only oral treatment for visceral, mucosal and cutaneous leishmaniasis approved by the U.S. Food and Drug Administration (\"FDA\") and the first Rx product launched in the U.S. by Profounda. \n\n\nThe skin sores of cutaneous leishmaniasis (\"CL\") usually heal on their own, even without treatment. However, this can take months or even years, and the sores can leave ugly scars. In 1-10% of patients with New World CL.1  Leishmania disseminates from the skin to the nasooropharyngeal mucosa, resulting in mucosal leishmaniasis (\"ML\") and destruction of nasal and pharyngeal structures. Death may occur due to complicating aspiration pneumonia. Mucosal leishmaniasis might not be noticed until years after the original sores healed. The best way to prevent mucosal leishmaniasis is to ensure adequate treatment of the cutaneous infection. Visceral leishmaniasis (\"VL\") is the result of systemic infection. Clinical manifestations include fever, hepatomegaly, splenomegaly, and bone marrow involvement with pancytopenia. VL is fatal if untreated. There are no other current FDA approved drugs for the treatment of CL or ML other than Impavido. \n\nClinicians can find out more about how to order Impavido for their patients or how to have the ability to have Impavido on consignment by visitin...